Novavax Profit Margin

Novavax (NVAX) currently reports a profit margin of -18.64% as of September 2026. That compares with 32.1% in the prior-year period — down 158.1% year over year. That is below the Healthcare sector average of 9.48%. Use the charts on this page to explore Novavax's profit margin history and peer comparisons.

Novavax's profit margin decreased from 32.1% to -18.64% — a 158.1% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Novavax's profit margin of -18.64% is lower than the Healthcare sector average of 9.48%. That is roughly 296.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Novavax's current -18.64% should be judged against Healthcare norms (sector average: 9.48%) and against NVAX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -18.64%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.48%. From there, open related valuation or income-statement pages for Novavax, and consider following NVAX for alerts when major investors trade the stock.